BiotechTube

AIN457 + AIN457 + Placebo AIN457

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uveitis

Conditions

Uveitis

Trial Timeline

Mar 1, 2010 → Jan 1, 2011

NCT ID
NCT01093846

About AIN457 + AIN457 + Placebo AIN457

AIN457 + AIN457 + Placebo AIN457 is a phase 3 stage product being developed by Novartis for Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01093846. Target conditions include Uveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)
✅Ixekizumab Prefilled SyringeEli LillyApproved
✅AdalimumabAbbVieApproved
✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved
🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
🔄Baricitinib + AdalimumabEli LillyPhase 3
🔄adalimumabAbbViePhase 3
🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01093846Phase 3Terminated

Competing Products

20 competing products in Uveitis

See all competitors
ProductCompanyStageHype Score
triamcinolone acetonide (Triesence®)Clearside BiomedicalPhase 1/2
22
4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3
30
Baricitinib + AdalimumabEli LillyPhase 3
44
Ixekizumab Prefilled SyringeEli LillyApproved
39
adalimumabAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
Adalimumab + Prednisone + PlaceboAbbViePhase 3
40
AdalimumabAbbVieApproved
43
FTY720 + Oral CorticosteroidNovartisPhase 2
27
AIN457NovartisPhase 3
32
MyforticNovartisPre-clinical
22
LFG316 + Conventional TherapyNovartisPhase 2
35
RanibizumabNovartisPhase 2
35
AIN457 + PlaceboNovartisPhase 3
32
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
AEB071NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32
Myfortic + DecortinNovartisPhase 3
40
AIN457 + AIN 457 + AIN457NovartisPhase 2
35
AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3
32